Company’s 36-month beta value is 1.99.Analysts have differing opinions on the stock, with 5 analysts rating it as a “buy,” 2 as “overweight,” 9 as “hold,” and 0 as “sell.”
The public float for TXG is 105.63M, and currently, short sellers hold a 15.16% ratio of that floaft. The average trading volume of TXG on June 25, 2025 was 3.77M shares.
TXG) stock’s latest price update
10x Genomics Inc (NASDAQ: TXG)’s stock price has gone rise by 3072852 in comparison to its previous close of 10.79, however, the company has experienced a -1.09% decrease in its stock price over the last five trading days. newsfilecorp.com reported 2025-06-18 that Toronto, Ontario–(Newsfile Corp. – June 18, 2025) – Torex Gold Resources Inc. (the “Company” or “Torex”) (TSX: TXG) announces the results of its 2025 annual and special meeting of shareholders (the “Meeting”) held virtually today. ITEM 1. ELECTION OF DIRECTORS At the Meeting, all director nominees listed in the Company’s management information circular (the “Circular”) dated May 7, 2025, were elected as directors of the Company.
TXG’s Market Performance
TXG’s stock has fallen by -1.09% in the past week, with a monthly rise of 27.52% and a quarterly rise of 4.81%. The volatility ratio for the week is 1.55% while the volatility levels for the last 30 days are 3.28% for 10x Genomics Inc The simple moving average for the past 20 days is 8.80% for TXG’s stock, with a -18.89% simple moving average for the past 200 days.
Analysts’ Opinion of TXG
Many brokerage firms have already submitted their reports for TXG stocks, with Leerink Partners repeating the rating for TXG by listing it as a “Market Perform.” The predicted price for TXG in the upcoming period, according to Leerink Partners is $12 based on the research report published on February 13, 2025 of the current year 2025.
Leerink Partners, on the other hand, stated in their research note that they expect to see TXG reach a price target of $35. The rating they have provided for TXG stocks is “Outperform” according to the report published on September 03rd, 2024.
Jefferies gave a rating of “Buy” to TXG, setting the target price at $24 in the report published on July 22nd of the previous year.
TXG Trading at 19.83% from the 50-Day Moving Average
After a stumble in the market that brought TXG to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -56.02% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TXG starting from Saxonov Serge, who sale 9,343 shares at the price of $8.30 back on May 22 ’25. After this action, Saxonov Serge now owns 1,083,625 shares of 10x Genomics Inc, valued at $77,540 using the latest closing price.
Hindson Benjamin J., the of 10x Genomics Inc, sale 7,485 shares at $8.30 during a trade that took place back on May 22 ’25, which means that Hindson Benjamin J. is holding 448,374 shares at $62,120 based on the most recent closing price.
Stock Fundamentals for TXG
Current profitability levels for the company are sitting at:
- -0.28 for the present operating margin
- 0.69 for the gross margin
The net margin for 10x Genomics Inc stands at -0.25. The total capital return value is set at -0.22. Equity return is now at value -22.03, with -17.20 for asset returns.
Based on 10x Genomics Inc (TXG), the company’s capital structure generated 0.1 points at debt to capital in total, while cash flow to debt ratio is standing at 0.71. The debt to equity ratio resting at 0.11. The interest coverage ratio of the stock is -57463.0.
Currently, EBITDA for the company is -133.99 million with net debt to EBITDA at 2.34. When we switch over and look at the enterprise to sales, we see a ratio of 1.7. The receivables turnover for the company is 11.89for trailing twelve months and the total asset turnover is 0.69. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.37.
Conclusion
In a nutshell, 10x Genomics Inc (TXG) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
